Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 63 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT04702464Phase 1
• A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal FunctionCompletedNCT04699877Phase 1
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
• Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsCompletedNCT04697511Phase 1
• Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT04695470Phase 2
• Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownNCT04693026Phase 3
• Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive, not recruitingNCT04691661Phase 2
• Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory OsteosarcomaCompletedNCT04690231Not applicable
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3
• Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
• Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) StudyActive, not recruitingNCT04685590Phase 2
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerActive, not recruitingNCT04685070Phase 2
• Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung CancerStatus unknownNCT04684017Phase 2
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
• Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast CancerStatus unknownNCT04681911Phase 2
• A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical CancerCompletedNCT04680988Phase 2
• Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A InducerStatus unknownNCT04680091Phase 1
• A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsStatus unknownNCT04679038Phase 1/2
• Flumatinib in CML-CP Patients With Ph+ Post Imatinib FailureStatus unknownNCT04677439Phase 4
• Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AMLWithdrawnNCT04676243Phase 3
• Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 CapsulesStatus unknownNCT04675060Phase 1
• Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male SubjectsCompletedNCT04675021Phase 1
• Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownNCT04675008Phase 2
• Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute LeukemiaStatus unknownNCT04674345Phase 2/3
• A Food-Effect Study of Hemay022 in Healthy ParticipantsStatus unknownNCT04673474Phase 1
• Effect of BMS-986165 on the Blood Levels of MetforminCompletedNCT04671953Phase 1
• An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.TerminatedNCT04671849Phase 1
• Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line ImmunotherapyStatus unknownNCT04670913Phase 2
• PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCTCompletedNCT04669210Phase 2
• TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingNCT04669067Phase 1/2
• Anlotinib to Malignant Brainstem GliomaStatus unknownNCT04668508Phase 2
• Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
• A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in BrazilWithdrawnNCT04666675Phase 3
• Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCStatus unknownNCT04665609Phase 3
• Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
• Cabozantinib With Topotecan-CyclophosphamideCompletedNCT04661852Phase 1
• Early Intervention With Acalabrutinib in Patients With High Risk CLLWithdrawnNCT04660045Phase 2
• A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Status unknownNCT04659785Phase 1/2
• Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in ChildrenStatus unknownNCT04659733Phase 1
• A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04657224Phase 1
• Lenvatinib in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04656249Phase 2
• Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)CompletedNCT04649723Phase 1
• Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid TumorCompletedNCT04648254Phase 1
• Tepotinib in Solid Tumors Harboring MET AlterationsStatus unknownNCT04647838Phase 2
• World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 TreatmentsStatus unknownNCT04647669Phase 3
• Study of Acalabrutinib and Tafasitamab in MZL PatientsActive, not recruitingNCT04646395Phase 2
• A Trial of AK104 Plus Anlotinib in NSCLCCompletedNCT04646330Phase 1/2
• Fruquintinib Food Effect and Proton Pump Inhibitor StudyCompletedNCT04645940Phase 1
• A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesStatus unknownNCT04643847Phase 2
• Zanubrutinib in Participants With Active Proliferative Lupus NephritisCompletedNCT04643470Phase 2
• Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
• Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicable
• A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Phase 2
• A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
• CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.Active, not recruitingNCT04639362Phase 2
• A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
• A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCStatus unknownNCT04636593Phase 2
• PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTSCompletedNCT04634565Phase 1
• Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT04632758Phase 3
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2
• Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationActive, not recruitingNCT04626024Phase 2
• A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
• Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2
• Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerStatus unknownNCT04624711Phase 2
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisActive, not recruitingNCT04624230Phase 3
• Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19Status unknownNCT04622865Phase 2
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
• XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT04622072Phase 1
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)Active, not recruitingNCT04621188Phase 2
• Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyStatus unknownNCT04620837Phase 2
• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal CancerWithdrawnNCT04620473Phase 2
• A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerCompletedNCT04620330Phase 2
• A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer PatientsStatus unknownNCT04619563Phase 2
• A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung CancerStatus unknownNCT04619537Phase 2
• A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.TerminatedNCT04619433Phase 3
• HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
• Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionTerminatedNCT04617054Phase 2
• The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsStatus unknownNCT04614740Phase 1/2
• Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid CancerStatus unknownNCT04612894Phase 2
• Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04609176Phase 2
• Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Active, not recruitingNCT04608318Phase 3
• Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast CancerStatus unknownNCT04605575Phase 2
• Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.Active, not recruitingNCT04604067Phase 2
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingNCT04603807Phase 3
• Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT04595747Phase 2
• A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT04594928Phase 1
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male ParticipantsCompletedNCT04591262Phase 1
• Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian CancerStatus unknownNCT04590625Phase 2
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
• Cabozantinib in Hepatocellular CarcinomaActive, not recruitingNCT04588051Phase 2
• Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsCompletedNCT04587713Phase 1
• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586023Phase 3
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586010Phase 3

← Tyrosine Kinase Inhibitors overview